Enliven Therapeutics Q3 2026 Results: Net Loss of $27.7M, Loss Widens
Enliven Therapeutics reported a significant increase in liquidity, with cash, cash equivalents, and marketable securities totaling approximately $884.4 million as of September 30, 2026, compared to $462.6 million at year-end 2025. The company is advancing its clinical pipeline, specifically relcobatinib (ELVN-001), and preparing for the ENABLE-2 Phase 3 pivotal trial.
- Key figure
- Net loss $27.7M